Truist raised the firm’s price target on Glaukos to $125 from $120 and keeps a Buy rating on the shares. The company’s Q1 results were “solid”, with the beat and raise being highlighted by implied iDose upside, the analyst tells investors in a research note. As long as iDose momentum is building, investors can stay excited and the “stock can work”, Truist added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS: